Larimar Therapeutics (LRMR) PT Lowered to $5 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Price: $2.76 +8.66%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Baird analyst Joel Beatty lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $5.00 (from $7.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Flutter Entertainment (FLUT) PT Lowered to $124 at Stifel
- GXO Logistics Inc. (GXO) PT Raised to $72 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
